X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3416) 3416
Book Review (1101) 1101
Publication (180) 180
Book Chapter (20) 20
Conference Proceeding (18) 18
Book / eBook (4) 4
Magazine Article (3) 3
Web Resource (2) 2
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (3038) 3038
humans (2707) 2707
diabetes mellitus, type 2 - drug therapy (1872) 1872
dipeptidyl-peptidase iv inhibitors - therapeutic use (1795) 1795
hypoglycemic agents - therapeutic use (1333) 1333
male (1323) 1323
animals (1125) 1125
type 2 diabetes (1073) 1073
female (1030) 1030
endocrinology & metabolism (932) 932
diabetes (873) 873
middle aged (801) 801
glucagon-like peptide-1 (790) 790
pharmacology & pharmacy (694) 694
aged (651) 651
dipeptidyl-peptidase iv inhibitors - pharmacology (634) 634
dipeptidyl peptidase 4 - metabolism (604) 604
dipeptidyl-peptidase iv inhibitors - adverse effects (571) 571
sitagliptin (555) 555
treatment outcome (554) 554
diabetes mellitus, type 2 - blood (532) 532
glucose (519) 519
adamantane - analogs & derivatives (497) 497
hypoglycemic agents - adverse effects (465) 465
adult (438) 438
glycemic control (433) 433
metformin (430) 430
hypoglycemic agents (428) 428
blood glucose - metabolism (426) 426
double-blind (426) 426
drug therapy, combination (420) 420
mice (415) 415
dipeptidyl peptidase-4 inhibitor (411) 411
insulin (409) 409
analysis (386) 386
rats (384) 384
sitagliptin phosphate (383) 383
blood glucose - drug effects (382) 382
care and treatment (372) 372
metformin - therapeutic use (371) 371
adamantane - therapeutic use (366) 366
hypoglycemic agents - pharmacology (363) 363
diabetes mellitus (360) 360
risk factors (339) 339
dipeptidyl-peptidase iv inhibitors - administration & dosage (337) 337
vildagliptin (323) 323
research (320) 320
triazoles - therapeutic use (310) 310
type-2 diabetes-mellitus (309) 309
drug therapy (307) 307
diabetes mellitus, type 2 - complications (305) 305
pyrazines - therapeutic use (304) 304
hypoglycemic agents - administration & dosage (296) 296
glycated hemoglobin a - metabolism (291) 291
diabetes therapy (288) 288
internal medicine (288) 288
type 2 diabetes mellitus (284) 284
peptides (283) 283
beta-cell function (280) 280
safety (277) 277
medicine, general & internal (276) 276
abridged index medicus (269) 269
diabetes mellitus, type 2 - metabolism (269) 269
dipeptidyl peptidase-4 inhibitors (269) 269
pyrrolidines - therapeutic use (263) 263
dextrose (260) 260
dipeptidyl-peptidase-iv (258) 258
peptidase (258) 258
efficacy (256) 256
glp-1 (253) 253
dpp-4 inhibitor (247) 247
glucagon (241) 241
nitriles - therapeutic use (241) 241
health aspects (234) 234
sulfonylurea compounds - therapeutic use (234) 234
incretins - therapeutic use (225) 225
improves glycemic control (223) 223
double-blind method (220) 220
mellitus (220) 220
dipeptidyl-peptidase iv inhibitors (218) 218
biochemistry & molecular biology (214) 214
linagliptin (214) 214
therapy (213) 213
medicine & public health (211) 211
medicine, research & experimental (211) 211
dipeptidyl peptidase-iv (208) 208
clinical trials (204) 204
dpp-4 inhibitors (199) 199
hyperglycemia (199) 199
diabetes mellitus, type 2 - physiopathology (197) 197
insulin resistance (197) 197
cardiac & cardiovascular systems (195) 195
risk (195) 195
dosage and administration (190) 190
physiological aspects (190) 190
glucagon-like peptide-1 receptor (188) 188
hypoglycemia (187) 187
insulin - therapeutic use (187) 187
dipeptidyl peptidase 4 (183) 183
dipeptidyl peptidase iv (181) 181
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3294) 3294
German (29) 29
Japanese (29) 29
French (27) 27
Spanish (18) 18
Hungarian (8) 8
Czech (7) 7
Italian (5) 5
Polish (4) 4
Russian (4) 4
Dutch (3) 3
Chinese (2) 2
Danish (2) 2
Croatian (1) 1
Korean (1) 1
Portuguese (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 10/2013, Volume 369, Issue 14, pp. 1317 - 1326
Saxagliptin, a new oral antihyperglycemic drug in the DPP-4 inhibitor class, had no effect on the risk of cardiovascular events in patients with type 2... 
ALL-CAUSE | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | EVENTS | GLUCOSE CONTROL | MICROALBUMINURIA | DISEASE | CLINICAL-USE | PREVENTION | RISK | DEATH | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Hospitalization - statistics & numerical data | Male | Adamantane - therapeutic use | Aged, 80 and over | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Hypoglycemia - chemically induced | Heart Failure - epidemiology | Diabetes Mellitus, Type 2 - complications | Adamantane - adverse effects | Adamantane - analogs & derivatives | Hypoglycemic Agents - therapeutic use | Cardiovascular Diseases - etiology | Dipeptides - therapeutic use | Double-Blind Method | Pancreatitis - epidemiology | Dipeptides - adverse effects | Kaplan-Meier Estimate | Pancreatitis - chemically induced | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Complications and side effects | Patient outcomes | Dosage and administration | Drug therapy | Heart diseases | Risk factors | Saxagliptin | Myocardial infarction | Cerebral infarction | Heart attacks | Peptidase | Diabetes mellitus | Pancreatitis | Cardiovascular disease | Angina | Patients | Heart rate | Ischemia | Diabetes | Cardiovascular diseases | Diabetes mellitus (non-insulin dependent) | Index Medicus | Abridged Index Medicus
Journal Article
Diabetes Care, ISSN 0149-5992, 10/2012, Volume 35, Issue 10, pp. 2076 - 2082
Journal Article
Atherosclerosis, ISSN 0021-9150, 2013, Volume 227, Issue 2, pp. 349 - 354
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 09/2007, Volume 9, Issue 5, pp. 733 - 745
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2013, Volume 369, Issue 14, pp. 1327 - 1335
Alogliptin, a new antihyperglycemic agent of the DPP-4 class, was shown to have no significant effect on cardiovascular risk over a median treatment period of... 
INHIBITOR ALOGLIPTIN | MEDICINE, GENERAL & INTERNAL | MYOCARDIAL-INFARCTION | CLINICAL-TRIALS | VASCULAR OUTCOMES | RISK | COMPLICATIONS | THERAPIES | CARDIOVASCULAR SAFETY | MELLITUS | BLOOD-GLUCOSE CONTROL | Hypoglycemic Agents - therapeutic use | Double-Blind Method | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Uracil - therapeutic use | Male | Myocardial Infarction - complications | Myocardial Infarction - drug therapy | Uracil - adverse effects | Angina, Unstable - drug therapy | Piperidines - therapeutic use | Angina, Unstable - complications | Piperidines - adverse effects | Cardiovascular Diseases - mortality | Female | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Diabetes Mellitus, Type 2 - complications | Uracil - analogs & derivatives | Type 2 diabetes | Care and treatment | Acute coronary syndrome | Patient outcomes | Risk factors | Myocardial infarction | Heart attacks | Cardiovascular disease | Angina | Drug development | Hemoglobin | Diabetes mellitus (non-insulin dependent) | Drug dosages | Cerebral infarction | Stroke | Peptidase | Statistical analysis | Diabetes mellitus | Pancreatitis | Committees | FDA approval | Hypoglycemia | Angina pectoris | Studies | Product development | Diabetes | Acute coronary syndromes | Cardiovascular diseases | Health risk assessment | Cancer | Index Medicus | Abridged Index Medicus
Journal Article